Clinical Trial Update: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED [Phase 2]

View source ↗

Summary

A Phase 2 trial of KPI-012 ophthalmic solution for persistent corneal epithelial defect was terminated; no efficacy or safety conclusions are provided in this u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Corneal Epithelial Defect

Drugs mentioned

• KPI-012 ophthalmic solution

Snippet

Sponsor: Combangio, Inc | Conditions: Persistent Corneal Epithelial Defect | Phase 2 | Status: TERMINATED